DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation

Trends in Pharmacological Sciences

Volumn 28, Issue 9, 2007, Pages 448-452

  Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARACHIDONIC ACID; CERIVASTATIN; CYTOCHROME P450; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 4A; CYTOKINE; DIHYDROXYICOSATRIENOIC ACID; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FLUINDOSTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LINOLEIC ACID; NIFEDIPINE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MONOCYTE; NONHUMAN; PAIN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPOXIDE HYDROLASES; HOMEOSTASIS; HUMANS; HYPERTENSION; INFLAMMATION;

EID: 34548495819     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.08.002     Document Type: Article

References (40)

1. Capdevila J.H., and Falck J.R. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat. 68-69 (2002) 325-344
2. Moghaddam M.F., et al. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat. Med. 3 (1997) 562-566
3. Michaelis U.R., and Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol. Ther. 111 (2006) 584-595
4. Spector A.A., and Norris A.W. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol. 292 (2007) C996-C1012
5. Larsen B.T., et al. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol. Sci. 28 (2007) 32-38
6. Node K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
7. Kozak W., et al. 11,12-Epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp. Biol. Med (Maywood). 228 (2003) 786-794
8. Spiecker M., and Liao J. Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc. Med. 16 (2006) 204-208
9. Smith K.R., et al. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2186-2191
10. Pang S.T., et al. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 143 (2002) 4897-4906
11. Fleming I., et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. 88 (2001) 44-51
12. Fichtlscherer S., et al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109 (2004) 178-183
13. Granville D.J., et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1321-1326
14. Yu B.N., et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin. Chim. Acta 348 (2004) 57-61
15. + channel current in cultured rat hippocampal astrocytes. Neuroscience 143 (2006) 703-716
16. Fleming I. Cytochrome P450 and vascular homeostasis. Circ. Res. 89 (2001) 753-762
17. Viswanathan S., et al. Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J. Am. Coll. Nutr. 22 (2003) 502-510
18. Yang B., et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol. Pharmacol. 60 (2001) 310-320
19. DeLozier T.C., et al. Detection of human CYP2C8, CYP2C9 and CYP2J2 in cardiovascular tissues. Drug Metab. Dispos. 35 (2007) 682-688
20. Pokreisz P., et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 47 (2006) 762-770
21. Imig J.D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289 (2005) F496-F503
22. Imig J.D., et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
23. Sinal C.J., et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275 (2000) 40504-40510
24. Luria A., et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 282 (2007) 2891-2898
25. Seubert J.M., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99 (2006) 442-450
26. Fornage M., et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the coronary artery risk development in young adults (CARDIA) study. Circulation 109 (2004) 335-339
27. Ohtoshi K., et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331 (2005) 347-350
28. Przybyla-Zawislak B.D., et al. Polymorphisms in human soluble epoxide hydrolase. Mol. Pharmacol. 64 (2003) 482-490
29. Sato K., et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J. Hum. Genet. 49 (2004) 29-34
30. Fornage M., et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum. Mol. Genet. 14 (2005) 2829-2837
31. Newman J.W., et al. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J. Lipid Res. 43 (2002) 1563-1578
32. Wang M.H., et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J. Pharmacol. Exp. Ther. 284 (1998) 966-973
33. Gauthier K.M., et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ. Res. 90 (2002) 1028-1036
34. Finta C., and Zaphiropoulos P.G. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 63 (2000) 433-438
35. Wang H., et al. Cloning, expression, and characterization of three new mouse cytochrome P450 enzymes and partial characterization of their fatty acid oxidation activities. Mol. Pharmacol. 65 (2004) 1148-1158
36. Fisslthaler B., et al. Nifedipine increases cytochrome P4502C expression and EDHF-mediated responses in coronary arteries. Hypertension 36 (2000) 270-275
37. Bauersachs J., et al. Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc. Res. 54 (2002) 669-675
38. Fang X., et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H2412-H2420
39. Seidegard J., et al. Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood. Cancer Res. 44 (1984) 3654-3660
40. Inceoglu B., et al. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82 (2007) 42-49